CD274 and non-small cell lung carcinoma: The current and future developments of T-DXd will include investigations of the activity of this drug toward brain metastases (phase II trial ELPIS, NCT06250777) or in the first-line setting administered alone in two phase III trials controlled for SoC chemotherapy + ICI in patients with HER2 MUT NSCLC (DESTINY-lung04) (NCT05048797), or with HER2 OE/PD-L1 intermediate NSCLC (DESTINY-Lung06) (NCT06899126), or in association with rilvegostomig with or whithout carboplatin (phase Ib DESTINY-Lung03 part 4) in patients with HER2 OE NSCLC [120].